pegylated liposomal doxorubicin + cyclophosphamide + trastuzumab + paclitaxel

This is a **combination chemotherapy regimen** for breast cancer, especially useful for patients with HER2-positive disease. The combination consists of: - **Pegylated liposomal doxorubicin**: an anthracycline antibiotic delivered via polyethylene glycol-coated liposomes, minimizing cardiac and systemic toxicity while maintaining tumor-targeted efficacy[1][3][5][7][9]. - **Cyclophosphamide**: an alkylating agent that interferes with DNA replication, leading to cell death. - **Trastuzumab**: a monoclonal antibody targeting the human epidermal growth factor receptor 2 (**HER2**), inhibiting cancer cell growth and survival. - **Paclitaxel**: a microtubule stabilizer that prevents cell division, used extensively for breast cancer in both early and advanced stages[2][4][6][8][10]. Combined regimens such as this are used to achieve synergistic antitumor effects and have been shown to provide robust responses with reduced cardiac toxicity, offering alternatives to conventional doxorubicin-based combinations[1][3][5][9]. This regimen is mainly indicated for **breast cancer**, particularly HER2-positive disease[1][9].